Invented in South Africa
Reven’s RJX Technology was invented in South Africa. Originally, development of RJX technology was dedicated to assist patients who had contracted the HIV virus and were battling devastating immune system challenges that reduced their quality of life and chance of survival.
Paving the Pathway
In the course of development, substantial resources were deployed into stabilizing the RJX formulation to increase its stability and prolong its expiration from hours to months to years. After a five-year effort, we succeeded in manufacturing RJX through a stable process as required to enter the FDA drug development path and began manufacturing in the United States in 2013.
What is RJX
RJX is an intravenous (IV) drug technology platform formulated to provide multimodal support to cells. The platform approach enables us to customize treatment dosage and frequency according to different therapeutic interests. The RJX platform technology is designed to target areas of metabolic function. For example: quiescing the inflammation cascade and immune modulation synergistically, while modulating the microenvironment in which cells interact with our bloodstream and ultimately affecting the microenvironment within cells themselves.
RJX is a stand-alone drug and a flexible formulation developed with a proprietary process to target areas of immunologic function without the need for stabilizers and preservatives.
RJX will shift current treatment paradigms across a range of disease states that are driven by inflammatory processes to improve outcomes, mitigate devastating impacts for patients and lower the costs of care dramatically.
Understand & Address Challenges
of inflammation and complexity of the immune response
Rational & Proven Formulation
known and approved pharmaceutical molecules (APIs)
easy administration and immediate impact in critical care
Multimodal - 1st in Class
There is a significant “polypharmacy” crisis in medicine in which multiple medicines are prescribed to treat symptoms of disease. Such a focus on symptoms, as opposed to treating the roots of cell dysfunction, has led to simultaneous use of many “single-mode of action” drugs that often end up competing with one another to promote new imbalances.
The RJX technology is designed to “reboot” the cellular process by knocking on natural doors at the cellular level, but in an entirely new and multi-faceted way from existing drugs and therapies. Multiple modes of action are believed to work together simultaneously to drive cellular restoration at the foundation of each cell, triggering the system of the body towards balance in the process.
Reven believes our “first in class” technology platform will pave the way to shift current prescription paradigms, in some cases mitigating the need for many drugs by focusing on the sources of cellular distress instead.